bioRxiv · 10.1101/2020.02.25.964908
Bacterial immune evasion proteins: The therapeutic potential of CHIPS
Abstract
Bacterial pathogens have evolved to secrete strong anti-inflammatory proteins that target the immune system. It was long speculated whether these virulence factors could serve as therapeutics in diseases in which abnormal immune activation plays a role. We adopted the secreted Chemotaxis Inhibitory Protein of Staphylococcus aureus (CHIPS) as a model virulence factor-based therapeutic agent for diseases in which C5aR1 stimulation plays an important role. We show that administration of CHIPS in human C5aR1 knock-in mice successfully dampens C5a mediated neutrophil migration during immune complex-initiated inflammation. Subsequent CHIPS toxicology studies in animal models were promising. However, during a small phase-I trial, healthy human volunteers showed adverse effects directly after CHIPS administration. Subjects showed clinical signs of anaphylaxis with mild leukocytopenia and increased C-reactive protein concentrations, suggesting an inflammatory response, which are believed to be related to the presence of relatively high circulating anti-CHIPS antibodies. Even though our data in mice shows CHIPS as a potential anti-inflammatory agent, safety issues in human subjects temper the use of CHIPS in its current form as a therapeutic candidate. The use of staphylococcal proteins, or other bacterial proteins, as therapeutics or immune-modulators in humans is severely hampered by pre-existing circulating antibodies.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tromp, A., Zhao, Y., Jongerius, I., Heezius, E. C., Abrial, P., Ruyken, M., van Strijp, J., de Haas, C. J. C., Spaan, A., van Kessel, K. P. M., Henry, T., Haas, P.-J. A.. 2020-02-28. Bacterial immune evasion proteins: The therapeutic potential of CHIPS. https://doi.org/10.1101/2020.02.25.964908
Cite the original work for its findings. Save a collection to share your selection of sources.